Last reviewed · How we verify
Induction of ovulation in polycystic ovarian syndrome
Approved treatments
- Glucophage · Generic (originally Merck Serono/Lipha)
Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia. - Glucophage · Dr. Reddy's Laboratories Limited
- Femara · M.D. Anderson Cancer Center
- Femara · Novartis AG
Letrozole reduces estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogens.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Induction of ovulation in polycystic ovarian syndrome patent landscape — cliff calendar, originator estates, attackable patents
- Induction of ovulation in polycystic ovarian syndrome treatment landscape brief
- Induction of ovulation in polycystic ovarian syndrome treatment updates RSS
Frequently asked questions about Induction of ovulation in polycystic ovarian syndrome
What drugs treat Induction of ovulation in polycystic ovarian syndrome?
Tracked treatments include Glucophage, Femara.
What is the treatment for Induction of ovulation in polycystic ovarian syndrome?
Standard treatment for Induction of ovulation in polycystic ovarian syndrome includes Glucophage, Femara. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Induction of ovulation in polycystic ovarian syndrome patent cliff · Induction of ovulation in polycystic ovarian syndrome CI report
- Treatment: Glucophage · Generic (originally Merck Serono/Lipha)
- Treatment: Glucophage · Dr. Reddy's Laboratories Limited
- Treatment: Femara · M.D. Anderson Cancer Center
- Treatment: Femara · Novartis AG
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing